Aims: Lack of adherence to smoking cessation medication regimens is assumed to play a significant role in limiting their effectiveness. This study aimed to assess evidence for this assumption.
Introduction
Data from numerous randomised controlled trials clearly demonstrate the effectiveness of nicotine replacement therapy (NRT) (1), bupropion (2) and varenicline (3) in promoting longterm abstinence from smoking. However, some population studies suggest that pharmacotherapy may be considerably less effective outside clinical trials (4) . One possible explanation for the finding of lower effectiveness in the 'real world' is that many smokers fail to adhere to treatment recommendations, i.e. they tend to take inadequate doses (5, 6) or discontinue treatment early (7) . The amount of medication taken is likely to have a moderating effect on the effectiveness of drugs used to assist quit attempts. In randomised controlled trials, great care is being taken to ensure good patient adherence. Nevertheless, a substantial proportion of study participants do not appear to follow dosing instructions: In one early trial on nicotine gum in which patients were advised to use their medication for at least three months, 43% of participants in the active treatment arm stopped taking the gum within 4 weeks (8) . Similarly high rates of early discontinuation have been reported for the nicotine patch (9), bupropion (10) and varenicline (11) . There is evidence to suggest that adherence to cessation medication is even lower outside clinical trials: In one retrospective survey from the United States, past NRT users who had bought their medication over the counter reported a median treatment duration of 9.8 days (12) which is in contrast with manufacturer recommendations (at least 8 weeks). In one prospective study from China, 84% of participants used NRT for less than 4 weeks, and 44% used it for less than 7 days (13).
There is currently no consensus on what defines adequate adherence in the context of smoking cessation medication. Adherence can be defined as compliance with recommendations on treatment duration or as compliance with a given dosing regimen. A general definition of good adherence to oral medication for the treatment of chronic diseases is use for at least 80% of the recommended duration (14) . Due to the diversity regarding the route of administration of medications to support smoking cessation (i.e., nasal, dermal or oral application), a universal criterion for adherence to these drugs is particularly hard to define. As a consequence, studies addressing adherence have used a wide range of definitions, e.g. 'taking at least 1 dose of medication for at least 80% of the treatment days' (15) , 'chewing at least 10 pieces of nicotine gum per day' (16) , and compliance indices calculated as the proportion of scheduled doses that had actually been taken (17, 18) .
Some of the reasons for early termination of cessation medication quoted most frequently in surveys include adverse events (12, 15, (19) (20) (21) , medication cost (12, 21) and no perceived need to take medication to stop smoking (12, 19, 20) . The most important precipitating factor for medication non-adherence, however, is likely to be relapse to smoking. In a recent inter-F o r R e v i e w O n l y net survey on the use of various medications to support a quit attempt (21) , 42% of participants stated they had stopped using the nicotine patch because they had relapsed to smoking; the corresponding proportions for other medications were 52% (nicotine gum), 46% (nicotine lozenge/tablet), 54% (nicotine inhaler), 26% (bupropion), and 18% (varenicline). Studies assessing the association between adherence to medication and success of a quit attempt might not yield valid results if non-adherence was not the cause but the consequence of relapse in a substantial proportion of cases. This effect which has also been termed 'reverse causality' (22) is likely to lead to an overestimation of the effect of treatment duration on quitting success as more treatment failures with short durations of treatment would be included in the analysis. This review aims to summarise the available evidence on the association between adherence and abstinence in studies controlling for potential bias due to relapse precipitating discontinuation of medication use.
Methods

Search strategy
Online databases (PubMed, WebOfScience, and the Cochrane Tobacco Addiction Group specialized register) were searched up to 28 February 2013 with the terms: 'smoking cessation AND (adherence OR compliance) AND (abstinence OR success)'. An additional search included the terms: '(nicotine replacement OR bupropion OR varenicline) AND (adherence OR compliance)'. Search terms were inclusive in an attempt to locate all studies examining the association between adherence and abstinence. A hand-search of the reference lists of included studies was also carried out, and leading researchers in the field were contacted.
Studies identified by these searches were screened for eligibility by two reviewers (T.R. and A.H.), with 98.8% agreement. In six cases, consensus was reached by involving a third reviewer (J.B.) who was blinded to the other reviewers' assessments. Details of the method of data collection, outcome measures, recall period, participant characteristics, sample size, response rate and analysis method were extracted and compiled into a table independently by two researchers (T.R. and A.H). All discrepancies were checked against the study papers, discussed and resolved.
Inclusion and exclusion criteria
We included primary and secondary analyses of prospective randomised controlled trials and observational studies which specifically addressed the association between medication adherence and abstinence in adult smokers. Due to potential confounding by recall bias, purely retrospective surveys were not included. With regard to pharmacotherapies, only studies involving the use of nicotine replacement therapy, buproprion or varenicline (used alone or in combination) were included as these are considered first-line treatments in most countries (23, 24) . We only included original articles written in English and published in peer-reviewed journals. Review articles, personal communications to editors, commentaries, study protocols, case studies, studies on smoking reduction and studies involving pregnant women or adolescents were excluded.
As outlined above, an important potential confounder in studies assessing the association between treatment adherence and abstinence is relapse leading to non-adherence in which case non-adherence is not the cause but the consequence of relapse. There are two ways to control for this bias: a) establishing the chronological sequence of non-adherence and relapse during a study b) assessing adherence during a pre-specified treatment period and determine abstinence only in those who had been continuously abstinent throughout this period Only studies reporting a valid strategy to control for reverse causality were included in this review.
Outcome measures
There was no uniform definition of adherence; most studies used retrospective self-reports of drug use to assess adherence while some interviewed participants daily via an interactive voice response system or established adherence using medication dispensers with an electronic counting device fitted to the bottle cap. Details of the definitions and methods used in individual studies are given in Table 1 and Table S1 (online supplement of this article).
Abstinence was defined as the proportion of participants who achieved point prevalence, 7-day point prevalence or continuous abstinence up to a given time-point. The assessment of abstinence was based on self-report or biochemical validation by exhaled carbon monoxide or salivary cotinine concentrations, and different cut-off values were used in different studies.
Data analysis
Due to variation between the studies with regard to the definitions of adherence and abstinence, results could not be pooled statistically. Consequently, the evidence was synthesized in a narrative review. 
Results
Search results
The electronic literature search yielded 498 articles. For 119 of these, eligibility could not be determined from the abstract so full text versions were retrieved and studied in detail. Thirty further eligible articles were identified through a review of reference lists and one additional article through contacting experts in the field. Of the resulting 150 articles, 37 assessed the association between adherence and abstinence, but only five reported using a strategy to control for potential confounding by reverse causality and were thus included in this review.
The authors of one additional study (25) took a different approach to controlling for such confounding in that they adjusted for smoking status during the first three weeks of a trial in a logistic regression of predictors of abstinence at six weeks. In this regard, that study did not meet the inclusion criteria for this review; however, its findings were similar to the results of a study from the same group that was included in this review (22) .
Description of included studies
All five articles assessed the association between NRT use and abstinence; this research aim was explicitly stated in three studies (22, 26, 27) and addressed in sub-group analyses in the other two (28, 29) . Two articles presented secondary analyses of randomised controlled trials (22, 27) , and two articles provided data from prospective observational studies (26, 28) .
The only article reporting original results of a randomised controlled trial referred to a study of nicotine gum versus placebo in addition to nicotine patch treatment in a small sample (n = 96) of alcohol-dependent smokers in an early phase of out-patient alcohol treatment (29) .
One study was conducted in the United Kingdom (27) , one in the United States (29) , one enrolled patients in both countries (22) , and the two remaining studies were from Switzerland (26) and Germany (28) , respectively. Baseline sample sizes ranged from 92 to 1,030, study populations were predominantly white, the mean/median age of participants ranged from 40 to 47 years, 29% to 54% of participants were female, and the mean/median number of cigarettes smoked daily ranged from 20 to 25. The length of follow-up ranged from four weeks to two years. Each study took a different approach to measuring adherence (see below). Smoking outcome was assessed as continuous abstinence and validated by exhaled carbon monoxide (CO) in four of the five studies (22, 26, 27, 29) . The association between adherence and abstinence was assessed by means of a logistic regression in four and by a χ 2 test in one study (28) . Details of the 37 articles addressing the association between adherence and abstinence but not controlling for relapse as a cause for non-adherence are provided in Table S1 in the online supplement to this article. Information on included studies is summarised in Table 1 .
Summary of the evidence
Due to the heterogeneity of the studies discussed above, this section provides short narrative summaries of the five included studies.
1. Shiffman (22) conducted a secondary analysis of a randomised controlled trial of nicotine lozenges versus placebo in 1,030 smokers. Participants were instructed to use lozenges for 6 weeks. Adherence to study medication was monitored daily during the first two weeks of the trial, using an interactive voice response system. In the absence of an a priori definition of adherence, study participants were categorised as 'high' lozenge users or 'low' lozenge users based on a median split of the entire cohort. The mean number of lozenges used per day was 10.2 ± 2.5 in the 'high' users group and 5. at 3, 6 and 12 months. In order to control for confounding by non-adherence due to relapse, the final analysis only included participants that had remained abstinent during the first two weeks (n = 37). After adjusting for educational level, depression score, nicotine dependence and study site, more frequent use of study medication (gum or placebo) during the second week of the first two treatment weeks increased the odds of continuous abstinence at 3, 6 and 12 months by 4% (CI = 1% to 6%; p = 0.008), 4% (1% to 8%; p = 0.045) and 3% (-3% to 10%; p = 0.364), respectively.
4. Raupach et al. (28) followed up 369 participants of a hospital-based smoking cessation programme for 6 months who had been encouraged to purchase NRT themselves. Participants provided self-reports of continuous abstinence and treatment duration at the sixmonth telephone follow-up. In the absence of an a priori definition of adherence, this study considered a minimum treatment duration of five weeks to indicate good adherence. In order to control for confounding by non-adherence due to relapse, analysis of the association between adherence and abstinence was restricted to those who had either remained abstinent or relapsed only after discontinuing medication use (n = 127).
Within this sub-group, self-reported continuous abstinence rate at 6 months was significantly higher if medication had been used for at least five weeks (61.0% vs. 42.6%; p = 0.039). 
Discussion
Main findings of this review
The results of this review indicate that there is a substantial lack of high-quality studies assessing the association between treatment adherence and subsequent quitting success. The two studies with the most rigorous control for confounding by reverse causality (22, 27) both found a significant effect of the amount of medication taken and quit rates at four to six weeks. The only other study reporting a significant effect on continuous 6-month abstinence (28) was limited by its observational design, a lack of biochemical validation of smoking status and potential confounding by participant motivation and recall bias. The two remaining studies which did not find significant effects after one (29) and two (26) years appeared underpowered as sample sizes were small. Since all five studies that met our inclusion criteria addressed adherence to NRT products, no conclusions can currently be drawn on the association between adherence and treatment success for other first-line treatments such as bupropion and varenicline, or combinations of treatments.
Strengths and limitations
In order to ensure the inclusion of all relevant articles, two independent reviewers assessed all publications identified by an extensive search of the literature. Agreement between reviewers was high, and all discrepancies were resolved by involving a third independent reviewer. We used conservative inclusion criteria in order to restrict this review to studies with relatively rigid methodology. This led to the exclusion of one study (25) that did not control for reverse causality in the way set out in our criteria but produced similar results as a comparable study with a larger sample size.
Only original articles written in English were included in this review. A total of 25 Pubmed citations were excluded due to their being written in Spanish (n = 9), German (n = 8), Polish (n = 3), French (n = 2), Dutch (n = 1), Turkish (n = 1), or Japanese (n = 1). Six of these were review articles and had to be excluded for that reason, and one was a commentary. The abstracts of the remaining 18 articles were screened, and none of these assessed abstinence in relation to medication adherence. Thus, exclusion of articles not written in English is unlikely to have confounded our results.
Another limitation of this review is that we were unable to conduct quantitative quality assessments of the included studies. This was due to the fact that there are currently no universally accepted quality criteria for the type of studies included in this review; available tools to assess the quality of such studies have been criticised for their low reliability (32, 33) . Instead, we used our field-specific expertise to provide qualitative judgments on the quality of included studies. Only two of the five included studies reported results from randomisedcontrolled trials; however, these were derived from secondary analyses. Thus, the association between adherence and abstinence was not a primary endpoint of these studies. The remaining three studies enrolled specific patient groups (i.e., alcohol-dependent smokers or smokers highly motivated to quit who reported to a university-based cessation clinic) which limits the generalisability of their findings to a general smoker population. Sample size was below 100 in two studies, and drop-out rates approached 50% in one study. Finally, four of the five studies did not use an a priori definition of adherence. In summary, the quality of included studies was low to moderate, and more well-designed studies are clearly needed.
Interpretation of the available evidence is further hampered by the lack of a universal definition of adherence and a consensus on how to control for reverse causality. Recently, it has been suggested to report adherence as the percentage of prescribed amount or to directly calculate medication intake (27) . Excluding participants who stopped using NRT because they abandoned their quit attempt (28) would be desirable but can only be done if all relevant data are available. The alternative approach taken by some authors (i.e. relating adherence during a short interval at the beginning of a trial to abstinence at a later stage) is more problematic as it does not account for (non-)adherence between the initial adherence period and the time when the quit attempt ended. While one study on medium-term abstinence retrospectively assessed adherence throughout the entire treatment phase (28), the two other small studies assessing abstinence at one (29) or two years (26) only controlled for reverse causality during the first 2-4 weeks of the treatment phase. Thus, even in these studies, a residual bias arising from reverse causality cannot be excluded.
Suggestions for future research
The definitions of adherence used in these studies were not primarily based on theoretical considerations including the mode of action of pharmacotherapies but mainly derived post
hoc from the data (e.g., median split of the number of lozenges taken per day or an arbitrary cut-off of at least 5 weeks of treatment). The fact that relapse tends to occur early during a quit attempt (34) suggests that the first weeks of treatment are most important, but no firm conclusions can be drawn from the available literature. Identification of a minimum treatment duration (or amount of medication taken per day) for pharmacotherapy to be effective is important in order to design interventions that may increase adherence (35) (36) (37) (38) . Ideally, such interventions would be informed by an analysis of modifiable predictors of adherence.
Despite the lack of a universal (and clinically meaningful) definition of good adherence, a number of studies have reported on predictors of adherence. These studies used various designs including secondary analyses of randomised controlled trial data (19), prospective observations (13) and retrospective surveys (20, 39) . Factors that were found to be associated with better adherence by most studies included male gender (13), more advanced age (13, 15, 19, 20) , higher self-efficacy (19, 40) , lower smoking rate at study entry (15), and more intensive concomitant counselling (41). However, since non-adherence may be precipitated by relapse in up to 50% of cases (21), these might reflect characteristics associated with higher odds of successful quit attempts regardless of medication adherence. In fact, most of the predictors listed above have been found to independently increase quit rates in a number of studies (42).
In conclusion, we found some evidence in studies of nicotine replacement therapy that low rates of adherence may be limiting effectiveness in clinical trials. These findings need to be confirmed using more rigorous methods (e.g. by assessing adherence using medication dispenser systems with an electronic monitoring device (37) up to a pre-defined follow-up point or the end of a quit attempt). They also need to be extended to other stop smoking medications and to use of stop smoking medicines outside of clinical studies. 
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Supporting information
Additional Supporting Information may be found in the online version of this article: Table S1 : Characteristics of studies which were excluded due to a lack of control for confounding by non-adherence due to relapse relapse during the study period could precipitate non-adherence in which case a reverse causality must be assumed (i.e., relapse precipitates non-adherence). Studies aimed at demonstrating that continuous abstinence is causally linked to medication adherence need to control for confounding by reverse causality. This can be done by either excluding all participants who relapsed before stopping their medication or by assessing adherence during a pre-specified treatment period and determine abstinence only in those subjects who had been continuously abstinent throughout this period.
Review Questions
Is there an association between adherence to cessation medication and continuous abstinence from smoking if reverse causality is being controlled for?
Search terms
Smoking cessation AND (adherence OR compliance) AND (abstinence OR success); (nicotine replacement OR bupropion OR varenicline) AND (adherence OR compliance) The search terms are deliberately inclusive so that papers are not missed. 
Search procedure
The lead reviewer will select studies for inclusion in the review. A second reviewer will independently screen all papers for suitability (using the study eligibility for review form).
Data to be extracted -Study design -Study sample and selection -Outcome definition and measures -Recall period -Response rate -Analysis
Data extraction strategy
Details of the studies agreed to be eligible for the review will be extracted and compiled into tables by the lead researcher and double-checked. All details in the table will be examined by a second reviewer highlighting any errors in extraction or Data will be extracted and entered into the table by the lead reviewer and also independently by a second reviewer. Any discrepancies will be recorded, discussed and resolved. 
Tables of outcome
NOTES:
• If more than one definition of success is examined (e.g. 1 week abstinence and 6 months abstinence) the longest length of abstinence that was linked to adherence data will be included in the study (i.e. 6 months).
• Where the association has been examined over multiple countries, the combined data-set will be used where available in preference to those that examine the association within each country individually. 
